Skip to navigation Skip to content



Progressive MS Alliance Brings Together Researchers From Around the Globe to Identify Drug Targets That Can Stop and Reverse MS Progression – Paper Published

October 22, 2015

Eighty scientists and clinicians from around the world were convened in Boston in March 2015 by the International Progressive MS Alliance (Alliance) to discuss what is known and not known about the chain of events and mechanisms (known as “pathogenesis”) leading to progressive MS, which is characterized by the gradual loss of function. This is a key priority research area for the Alliance because unearthing details of these events will identify critical pathways that could be targeted by new therapies aimed at stopping progression and restoring function for the estimated 1 million people who live with a progressive form of MS.

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.